Halozyme Therapeutics, Inc. (HALO): Price and Financial Metrics

Halozyme Therapeutics, Inc. (HALO): $37.31

-0.88 (-2.30%)

POWR Rating

Component Grades













Add HALO to Watchlist
Sign Up

Industry: Biotech



in industry


  • Quality is the dimension where HALO ranks best; there it ranks ahead of 83.12% of US stocks.
  • The strongest trend for HALO is in Growth, which has been heading up over the past 177 days.
  • HALO ranks lowest in Momentum; there it ranks in the 4th percentile.

HALO Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for HALO is 3.89 -- better than 87.34% of US stocks.
  • HALO's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 602.19 -- higher than 95.25% of US-listed equities with positive expected earnings growth.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 8.11 for HALOZYME THERAPEUTICS INC; that's greater than it is for 86.73% of US stocks.
  • Stocks that are quantitatively similar to HALO, based on their financial statements, market capitalization, and price volatility, are INFA, PRGS, BRKR, ACIW, and VERI.
  • Visit HALO's SEC page to see the company's official filings. To visit the company's web site, go to www.halozyme.com.

HALO Valuation Summary

  • HALO's price/sales ratio is 7.1; this is 273.68% higher than that of the median Healthcare stock.
  • HALO's price/sales ratio has moved down 132.6 over the prior 232 months.

Below are key valuation metrics over time for HALO.

Stock Date P/S P/B P/E EV/EBIT
HALO 2023-03-24 7.1 27.5 23.1 22.3
HALO 2023-03-23 6.9 26.9 22.6 21.9
HALO 2023-03-22 6.7 26.2 22.0 21.5
HALO 2023-03-21 7.1 27.6 23.2 22.4
HALO 2023-03-20 7.1 27.8 23.3 22.5
HALO 2023-03-17 6.8 26.4 22.2 21.6

HALO Growth Metrics

    The 5 year price growth rate now stands at 79.34%.
  • The 5 year net income to common stockholders growth rate now stands at 30.98%.
  • The 2 year cash and equivalents growth rate now stands at 12.36%.
Over the past 52 months, HALO's revenue has gone up $378,922,000.

The table below shows HALO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 660.116 240.11 202.129
2022-09-30 580.623 240.173 211.197
2022-06-30 487.477 292.277 366.15
2022-03-31 471.567 288.941 434.923
2021-12-31 443.31 299.44 402.71
2021-09-30 463.01 267.844 409.104

HALO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • HALO has a Quality Grade of C, ranking ahead of 73.97% of graded US stocks.
  • HALO's asset turnover comes in at 0.493 -- ranking 84th of 682 Pharmaceutical Products stocks.
  • ARAV, XOMA, and MGNX are the stocks whose asset turnover ratios are most correlated with HALO.

The table below shows HALO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.493 0.814 0.250
2021-06-30 0.533 0.823 0.255
2021-03-31 0.510 0.832 0.224
2020-12-31 0.504 0.838 0.220
2020-09-30 0.378 0.831 0.053
2020-06-30 0.369 0.720 -0.037

HALO Price Target

For more insight on analysts targets of HALO, see our HALO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $52.82 Average Broker Recommendation 1.62 (Moderate Buy)

HALO Stock Price Chart Interactive Chart >

Price chart for HALO

HALO Price/Volume Stats

Current price $37.31 52-week high $59.46
Prev. close $38.19 52-week low $32.83
Day low $36.62 Volume 2,233,900
Day high $38.49 Avg. volume 1,606,470
50-day MA $45.70 Dividend yield N/A
200-day MA $47.34 Market Cap 5.05B

Halozyme Therapeutics, Inc. (HALO) Company Bio

Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. The company was founded in 1998 and is based in San Diego, California.

HALO Latest News Stream

Event/Time News Detail
Loading, please wait...

HALO Latest Social Stream

Loading social stream, please wait...

View Full HALO Social Stream

Latest HALO News From Around the Web

Below are the latest news stories about HALOZYME THERAPEUTICS INC that investors may wish to consider to help them evaluate HALO as an investment opportunity.

Halozyme Therapeutics (HALO) Down 34.4% Since Last Earnings Report: Can It Rebound?

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | March 23, 2023

Strength Seen in Halozyme Therapeutics (HALO): Can Its 5.3% Jump Turn into More Strength?

Halozyme Therapeutics (HALO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Yahoo | March 21, 2023

Medicare Negotiation Undercuts Biotech Stocks Regeneron, Halozyme

Confusion over new Centers for Medicare and Medicaid Services negotiating plans sent REGN and HALO stocks tumbling Thursday.

Yahoo | March 17, 2023

Dow Jones Hits Session Highs; Tesla Faces New Lawsuit From Customers, Agrees To Open 7500 Charging Stations

The Dow Jones Industrial Average rose throughout the session Thursday and closed near the day's highs. The blue chip index gained 1.2%, its best day since March 3. Intel was the Dow's clear leader, with a hefty 6% gain.

Yahoo | March 16, 2023


Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today provides an update on a decision by the Opposition Division of the European Patent Office ("EPO") regarding one of the Janssen Biotech, Inc. (Janssen) co-formulation patents for DARZALEX® (daratumumab) SC.

Yahoo | March 15, 2023

Read More 'HALO' Stories Here

HALO Price Returns

1-mo -21.65%
3-mo -34.43%
6-mo -5.64%
1-year -6.44%
3-year 107.39%
5-year 90.45%
YTD -34.43%
2022 41.51%
2021 -5.85%
2020 140.89%
2019 21.19%
2018 -27.79%

Continue Researching HALO

Want to see what other sources are saying about Halozyme Therapeutics Inc's financials and stock price? Try the links below:

Halozyme Therapeutics Inc (HALO) Stock Price | Nasdaq
Halozyme Therapeutics Inc (HALO) Stock Quote, History and News - Yahoo Finance
Halozyme Therapeutics Inc (HALO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8233 seconds.